Search

Displaying results 2141 - 2150 of 10000 in total
  1. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  2. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    [A193518] Adapalene has similar efficacy but a superior safety profile compared to tretinoin. … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.

  3. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901] … [A263126] These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue.

    Synonyms: N-Methionylleptin
  4. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [Helium-3] (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability. … [L44528] Hyperpolarized Xe-129 is chemically identical to non-polarized Xe-129, and xenon is a clear, colorless, monoatomic, inert, stable, noble gas.[L44523]

  5. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    [L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. … [A6921] Ofatumumab was first approved by the FDA in 2009.

  6. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant. … [A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational

  7. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of

  8. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  9. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression. … more common GABA<sub>A</sub> positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and extrasynaptic GABA<sub>A</sub> conductance due to binding to a non-benzodiazepine

  10. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. … Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors